R. Daniel Faga's Insider Trades & SAST Disclosures
R. Daniel Faga's most recent trade in AnaptysBio Inc was a trade of 305,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern R. Daniel Faga.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 305,500 | 305,500 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 107,350 | 107,350 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 34,678 | 438,036 (1%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 34,678 | 104,032 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,850 | 442,853 (1%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,850 | 35,700 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.60 per share. | 03 Jan 2025 | 13,033 | 425,003 (1%) | 0% | 14.6 | 190,282 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.30 per share. | 03 Jan 2025 | 6,387 | 436,466 (1%) | 0% | 15.3 | 97,721 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 160,000 | 160,000 | - | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.60 per share. | 22 Mar 2024 | 347,441 | 401,646 (1%) | 1% | 21.6 | 7,504,726 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Sale of securities on an exchange or to another person at price $ 22.78 per share. | 22 Mar 2024 | 145,940 | 752,087 (2%) | 0% | 22.8 | 3,325,185 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Sale of securities on an exchange or to another person at price $ 21.42 per share. | 22 Mar 2024 | 3,000 | 749,087 (2%) | 0% | 21.4 | 64,268 | Common Stock |
| AnaptysBio Inc | Daniel Faga R. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 17,850 | 904,893 (3%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 17,850 | 53,550 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Sale of securities on an exchange or to another person at price $ 21.81 per share. | 06 Jan 2024 | 6,866 | 898,027 (3%) | 0% | 21.8 | 149,747 | Common Stock |
| AnaptysBio Inc | R. Daniel Faga | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 379,620 | 379,620 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | R. Faga Daniel | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 138,710 | 138,710 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 194,900 | 194,900 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 71,400 | 71,400 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 887,043 | 887,043 (3%) | 3% | 0 | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Nov 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Nov 2021 | 2,321 | 2,321 | - | - | Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Daniel R. Faga | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 1,340 | 63,630 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Daniel R. Faga | EVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 194.38 per share. | 02 Feb 2021 | 1,340 | 30,638 (0%) | 0% | 194.4 | 260,469 | Common Stock |
| Mirati Therapeutics Inc | Daniel R. Faga | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 114.33 per share. | 02 Feb 2021 | 1,340 | 31,978 (0%) | 0% | 114.3 | 153,202 | Common Stock |
| Mirati Therapeutics Inc | Daniel R. Faga | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 10,979 | 10,979 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Daniel R. Faga | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 7,023 | 30,638 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Daniel R. Faga | EVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 216.33 per share. | 07 Jan 2021 | 2,613 | 23,615 (0%) | 0% | 216.3 | 565,270 | Common Stock |
| Mirati Therapeutics Inc | Daniel R. Faga | EVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 215.33 per share. | 07 Jan 2021 | 12 | 26,228 (0%) | 0% | 215.3 | 2,584 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges